Effect of PON1 on dichlorvos toxicokinetics

Na-Na Wang, Li Yuan, Heng Dai, Zhen-Kun Han, Min Zhao

ABSTRACT

Objectives To provide toxicokinetic and clinical evidence of the hydrolytic effect of paraoxonase-1 (PON1) on acute organophosphate poisoning in rats.

Methods 40 male Wistar rats were randomised into four equal groups. Dichlorvos administration group (A group) underwent dichlorvos injection (dissolved in corn oil) using intraperitoneal (ip) dose of 10 mg/kg. PON1 pretreatment group (B group) was injected with PON1 in the tail vein (intravenous), dose 9600 U/kg, 30 min prior to dichlorvos administration. In the treatment group (C group), atropine 0.05 mg/kg and pyraloxime chloride (PAM-CI) 120 mg/kg were injected intravenously within 2 min after dichlorvos administration. Finally, in the co-treatment group (D group), PON1 was injected intravenously with a dose of 9000 U/kg, 30 min prior to dichlorvos administration; atropine 0.05 mg/kg and PAM-CI 120 mg/kg were injected intravenously within 2 min after dichlorvos administration. Blood was collected after administration. Plasma dichlorvos concentration was detected by liquid chromatography-mass spectra (LC-MS) method and clinical signs were observed. Toxicokinetic parameters were calculated in a statistical moment model.

Results AUC (0 → ∞) in group B was statistically different from that in groups A and C (p < 0.05), while it was not different from group D (p > 0.05); there was no statistical difference between group A and group C (p > 0.05). The statistical results of Cmax were the same as those of AUC (0 → ∞). There were no differences of MRT between four groups (p > 0.05). Clinical signs can be improved by PON1 and atropine + PAM-CI, and co-treatment can relieve signs more effectively.

Conclusion PON1 can decrease the amount of dichlorvos that entered the blood, lowered the peak concentration and relieved clinical signs.

MATERIALS AND METHODS

Material

Dichlorvos (>99.5% pure) was obtained from Tianjin Agriculture Co., Ltd; acetonitrile, indomethacin and methanoic acid (chromatographic pure) were homemade reagents. Clean grade male Wistar rats, weighing 250–500 g, were obtained from Beijing Vital River Experimental Animal Co., Ltd. The animals were fed ad libitum in the experiment.

AKTA purifier automatic chromatography was manufactured by GE Company (Bridgeport, Connecticut, USA). TSQ Quantum Ultra, produced by Thermo Finnigan (San Jose, California, USA). Eppendorf 5417-R refrigerated centrifuge was manufactured by Eppendorf Company (Hamburg, Germany).

Dose schedule and sample collection

40 male Wistar rats were randomised into four equal groups. The dichlorvos administration group (A group) underwent dichlorvos injection (dissolved in corn oil) using intraperitoneal (ip) dose of 10 mg/kg. The PON1 pretreatment group (B group) was injected with PON1 in the tail vein (intravenous), dose 9600 U/kg, 30 min prior to dichlorvos administration (10 mg/kg ip). In the treatment group (C group), atropine 0.05 mg/kg and pyraloxime chloride (PAM-CI) 120 mg/kg were injected intravenously within 2 min after dichlorvos administration (10 mg/kg ip). In the co-treatment group (D group), PON1 was injected intravenously in a dose of 9000 U/kg, 30 min prior to dichlorvos administration (10 mg/kg ip); atropine 0.05 mg/kg and PAM-CI 120 mg/kg were injected intravenously within 2 min after dichlorvos administration.

Blood of 0.2 ml was collected at 3 min, 5 min, 10 min, 20 min, 30 min, 1 h, 2 h, 4 h and 6 h after administration from the eye veins. Blood was centrifuged at 5000 r for 3 min and the supernatant was collected and stored in –80°C for dichlorvos detection.

Serum paraoxonase-1 (PON1) is an A-esterase that is associated with high-density lipoprotein (HDLs). The products of PON1 gene exist widely in mammals, with the highest activity in liver and blood. It is involved in the detoxification of organophosphate insecticides, such as chlorpyrifos oxon, diazoxon, paraoxon and dichlorvos. As a result, it has been proposed that PON1 may have tissue damage from organophosphate compounds. Therefore, PON1 may prevent tissue damage from organophosphate toxicity, especially in the central nervous system. There have been studies designed to evaluate the protective effect of PON1 on organophosphates in vitro or by measuring inhibition of acetyl cholinesterase in different tissues, but studies on organophosphate concentration changes in vivo are rare. As a result, the protective effect of PON1 on organophosphates in vivo and in vitro or by measuring inhibition of acetyl cholinesterase in different tissues, but studies on organophosphate concentration changes in vivo are rare. 

In vitro or by measuring inhibition of acetyl cholinesterase in different tissues, but studies on organophosphate concentration changes in vivo are rare. As a result, the protective effect of PON1 on organophosphates in vivo and in vitro or by measuring inhibition of acetyl cholinesterase in different tissues, but studies on organophosphate concentration changes in vivo are rare. As a result, the protective effect of PON1 on organophosphates in vivo and in vitro or by measuring inhibition of acetyl cholinesterase in different tissues, but studies on organophosphate concentration changes in vivo are rare. As a result, the protective effect of PON1 on organophosphates in vivo and in vitro or by measuring inhibition of acetyl cholinesterase in different tissues, but studies on organophosphate concentration changes in vivo are rare. As a result, the protective effect of PON1 on organophosphates in vivo and in vitro or by measuring inhibition of acetyl cholinesterase in different tissues, but studies on organophosphate concentration changes in vivo are rare. As a result, the protective effect of PON1 on organophosphates in vivo and in vitro or by measuring inhibition of acetyl cholinesterase in different tissues, but studies on organophosphate concentration changes in vivo are rare.
consideration the severity of the reactions (0 = no reactions, 1 = mild reactions, 2 = moderate reactions, 3 = severe reactions, 4 = mortality). Because there were no deaths in the experiment, no rats scored 4.

**Purification of rabbit serum PON1**

Peroxidase was purified from rabbit serum as previously described in detail. The collected protein was subjected to centrifugal ultrafiltration on centrifuges YM-10 (Millipore, Billerica, Massachusetts, USA) so as to concentrate to >5000 U/ml. The enzyme was dissolved in buffer solution (156 mM NaCl, 0.1 mM CaCl2) for injection before usage.

**LC-MS method**

**Sample preparation**

Plasma aliquot of 50 μl was added to 2.5 μl of the internal standard indomethacin solution that was prepared in methanol of 50 mg/ml. Then, acetonitrile (100 μl) was added to the mixture. The resulting mixture was vortex-mixed for 1 min and then centrifuged at 12000 r for 5 min. The supernatant was filtered through a 0.45-μm Millex®-LH filter, and 20 μl of the filtrate was injected into the LC-APCI-MS.

**LC-MS condition**

The HPLC analysis was performed on a Diamonsil C18 column (150×4.6 mm inside diameter, 5 μm) equipped with a phenomenex C18 guard column (4×3.0 mm inside diameter) at room temperature. Fluid phase was used with solvent consisting of acetonitrile-water–methanoic acid (90:10:0.2, v/v/v) at a flow rate of 0.45 ml/min. The solutions were filtered through a 0.45 μm Millex®-LH filter before use.

A Thermo Finnigan TSQ Quantum Ultra tandem mass spectrometer equipped with an APCI interface operated in the positive ion mode. The capillary voltage was set to 4.2 kV. The spectrometer equipped with an APCI interface operated in the positive ion mode. The capillary voltage was set to 4.2 kV. The spectrometer equipped with an APCI interface operated in the positive ion mode. The capillary voltage was set to 4.2 kV. The spectrometer equipped with an APCI interface operated in the positive ion mode. The capillary voltage was set to 4.2 kV. The spectrometer equipped with an APCI interface operated in the positive ion mode. The capillary voltage was set to 4.2 kV. The spectrometer equipped with an APCI interface operated in the positive ion mode. The capillary voltage was set to 4.2 kV. The spectrometer equipped with an APCI interface operated in the positive ion mode. The capillary voltage was set to 4.2 kV. The spectrometer equipped with an APCI interface operated in the positive ion mode.

**RESULTS**

**Toxicokinetics of dichlorvos**

**Dichlorvos concentration**

The concentrations of dichlorvos in B group were statistically different from A group (p < 0.05), while atropine + PAM-CI did not alter dichlorvos concentration statistically (p > 0.05) (table 1).

**Dichlorvos toxicokinetics parameters**

The toxicokinetics parameter differences between four groups were performed by ANOVA. There were no statistical differences between AUC (0 → ∞) of groups A and C, but the effect of PON1 was obvious in groups B and D when compared with group A. There were no statistical differences between MRT (0 → ∞) of the four groups. Cmax was obtained by observing the peak concentrations in table 1. The statistical result coincided with that of AUC (0 → ∞) (table 2).

**Clinical signs**

The clinical signs were alleviated by PON1, atropine + PAM-CI and co-treatment, and the effect of PON1 was not different with atropine + PAM-CI statistically. However, co-treatment achieved the best effect (table 3).

**DISCUSSION**

The 1/2 LD50 (LD50, 18–20 mg/kg by ip) of dichlorvos was selected so that the most severe signs of poisoning would be elicited but no death arose through preliminary experiment. The

**Table 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>A group (μg/ml)</th>
<th>B group (μg/ml)</th>
<th>C group (μg/ml)</th>
<th>D group (μg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05</td>
<td>0.84 ± 0.05</td>
<td>0.76 ± 0.17</td>
<td>1.83 ± 0.40</td>
<td>0.76 ± 0.07</td>
</tr>
<tr>
<td>0.08</td>
<td>3.31 ± 0.31</td>
<td>1.22 ± 0.13</td>
<td>3.13 ± 0.27</td>
<td>1.33 ± 0.21</td>
</tr>
<tr>
<td>0.17</td>
<td>5.36 ± 0.63</td>
<td>2.91 ± 0.18</td>
<td>5.28 ± 0.55</td>
<td>2.90 ± 0.32</td>
</tr>
<tr>
<td>0.33</td>
<td>2.85 ± 0.30</td>
<td>1.57 ± 0.26</td>
<td>2.74 ± 0.42</td>
<td>1.54 ± 0.05</td>
</tr>
<tr>
<td>0.5</td>
<td>1.93 ± 0.26</td>
<td>0.99 ± 0.18</td>
<td>1.87 ± 0.34</td>
<td>0.95 ± 0.17</td>
</tr>
<tr>
<td>1</td>
<td>1.35 ± 0.22</td>
<td>0.64 ± 0.08</td>
<td>1.25 ± 0.10</td>
<td>0.64 ± 0.10</td>
</tr>
<tr>
<td>2</td>
<td>1.09 ± 0.21</td>
<td>0.35 ± 0.07</td>
<td>1.05 ± 0.16</td>
<td>0.35 ± 0.01</td>
</tr>
<tr>
<td>4</td>
<td>0.66 ± 0.16</td>
<td>0.23 ± 0.01</td>
<td>0.65 ± 0.09</td>
<td>0.23 ± 0.03</td>
</tr>
<tr>
<td>6</td>
<td>0.37 ± 0.06</td>
<td>0.22 ± 0.01</td>
<td>0.35 ± 0.02</td>
<td>0.21 ± 0.01</td>
</tr>
</tbody>
</table>

All the data were expressed as mean ± SD.

*p < 0.01, concentration data were compared with A group by t test. There were statistical differences between group B and group A and between group C and group A.
fore, it is postulated that co-treatment may be feasible in the treatment of human organophosphates poisoning. However, in the treatment of human organophosphates by measuring cholinesterase activities in different tissues.10–12 Our results provide further direct evidence by showing changes in concentration with PON1 pre-treatment. We also compared the hydrolytic effect of PON1 with atropine +PAM, the most widely used therapy clinically. The results of the study show that atropine +PAM does not affect the metabolism of dichlorvos, which is consistent with the findings of a previous study.13 Co-treatment does not alter the impact of PON1 on dichlorvos concentrations, which implies that there is no interaction between PON1 and atropine+PAM-CI; therefore, it is postulated that co-treatment may be feasible in the clinical treatment of human organophosphate-related toxicity.

We also investigated the clinical signs of the four groups. Decreased blood dichlorvos concentration in the PON1 pretreatment group resulted in better clinical outcome when compared with the dichlorvos administration group. At this dose, the PON1 effect is comparable to that of atropine+PAM-CI, which is the most common antidotal treatment used clinically. In addition, another novel finding in our study was that the clinical signs were relieved the most by co-treatment. This may have important implications on the future treatment of organophosphates poisoning.

Interest in PON1 arises from the hypothesis that individuals with low serum activity of this enzyme would be expected to have a diminished ability to metabolise organophosphates. This hypothesis implies that serum PON1 has a pivotal role in the detoxification of the organophosphate. After the hypothesis was raised, some studies have been designed to evaluate the protective effect of PON1 by pretreating animals with PON1 before organophosphates administration. Such studies are needed before any definite inference can be drawn on the role that serum paraoxonase levels have in the protective effect on insecticides. However, in the treatment of human organophosphate-related toxicity, antidotes are administered after exposure, so further investigations of PON1 should be conducted with PON1 administration after organophosphate exposure on the theoretical basis of protective function.

In conclusion, PON1 can hydrolyse organophosphates in vivo and improve clinical signs of organophosphate toxicity. The use of PON1 in organophosphates poisoning requires further investigations.

Funding National Natural Science Foundation of China (No. 30671778) and Technology of the Education Department of Liaoning Province (No. 05L480).

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Table 2: Toxicokinetics parameters of dichlorvos

<table>
<thead>
<tr>
<th>Parameter</th>
<th>A group</th>
<th>B group</th>
<th>C group</th>
<th>D group</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC(0–∞) (μMmin/ml)</td>
<td>11.24±1.63</td>
<td>4.25±0.41</td>
<td>10.71±0.97</td>
<td>4.67±0.99</td>
</tr>
<tr>
<td>MRT (h)</td>
<td>7.93±1.40</td>
<td>8.50±2.05</td>
<td>7.65±0.87</td>
<td>13.89±5.80</td>
</tr>
<tr>
<td>Cmax (μg/ml)</td>
<td>5.36±0.63</td>
<td>2.91±0.18</td>
<td>5.28±0.55</td>
<td>2.90±0.32</td>
</tr>
</tbody>
</table>

All the data were expressed as mean±SD.

Table 3: Clinical signs scores of four groups

<table>
<thead>
<tr>
<th>Group</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>A group</td>
<td>0</td>
</tr>
<tr>
<td>B group</td>
<td>0</td>
</tr>
<tr>
<td>C group</td>
<td>0</td>
</tr>
<tr>
<td>D group</td>
<td>2</td>
</tr>
</tbody>
</table>

Ridit analysis was used to analyse the differences between the data of clinical signs scores of four groups, where p<0.05 was regarded as significant.